Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC2375 | ONO 4817 |
| Broad spectrum MMP inhibitor; Ki values are 0.45, 0.73, 1.1, 1.1, 2.1, 42 and 2500 nM for MMP-12, MMP-2, MMP-8, MMP-13, MMP-9, MMP-3 and MMP-7 respectively and IC50 = 1600 nM for MMP-1). Displays no activity at other proteases up to a concentration of 100 μM. Exhibits antiangiogenic and anti-invasive properties on lung metastasis of murine renal cell carcinoma. | |
| BCC2379 | UK 370106 |
| Highly selective MMP-3 and MMP-12 inhibitor (IC50 values are 0.023, 0.042, 1.75, 2.3, 5.8, 30.4, 34.2 and 66.9 μM at MMP 3, 12, 8, 13, 7, 9, 2 and 14 respectively.) Inhibits fibronectin cleavage (IC50 = 320 nM) and has little effect on keratinocyte migration in vitro. Substantially inhibits MMP-3 in an ex vivo model of chronic dermal ulcers. | |
| BCC2381 | BC 11 hydrobromide |
| Selective urokinase (uPA) inhibitor (IC50 = 8.2 μM). Exhibits no activity at 8 other related enzymes. Inhibits clot lysis with no effect on clot formation. Also decreases viability of MDA-MB231 breast cancer cells in vitro. | |
| BCC2389 | NSC 687852 (b-AP15) |
| Inhibitor of 19S regulatory particle associated deubiquitinating enzymes (DUBs), UCHL5 and USP14. Shows minimal inhibition of UCHL-1, UCHL-3, USP2, USP7, USP, BAP1 and proteasome activity. Induces apoptosis by cathepsin D-dependent caspase-cleavage (IC50 = 0.5 μM). Displays antitumor activity in vivo. | |
| BCC2390 | Oncrasin 1 |
| Proapoptotic agent that induces abnormal nuclear aggregation of PKCι and suppresses RNA transcription. Exhibits antiproliferative effects against various human tumor cell lines with K-Ras mutations (IC50 ≤ 3 μM) with minimal effects on normal epithelial cells and inhibits human xenograft growth by 75% in vivo. | |
| BCC2391 | ARRY 520 trifluoroacetate |
| Potent kinesin spindle protein (KSP) inhibitor (IC50 = 6 nM); selective for KSP over >250 other receptors and kinases at a concentration of 10 μM. Displays robust antitumor activity in bortezomib-resistant xenografts either alone or in combination with bortezomib. Induces degradation of Mcl-1; exhibits comparable cytotoxic activity to taxol in epithelial ovarian cancer cells. Active in vivo. | |
| BCC2398 | SU 9516 |
| Potent, selective cdk2 inhibitor (IC50 values are 0.022, 0.04, 0.2, >10, >10, 18 and >100 μM for cdk2, cdk1, cdk4, PKC, p38, PDGFR and EGFR respectively). Inhibits pRb phosphorylation causing enhanced pRB/E2F complex formation and induces G1 and G2-M cell cycle arrest. Transcriptionally downregulates Mcl-1 and has antiproliferative, cytostatic and pro-apoptotic effects in vitro. | |
| BCC2399 | Cesium chloride |
| Potassium channel blocker; inhibits the pacemaker current (If) and the hyperpolarization-activated cationic current (Ih). Prevents activation of caspase-3 and neuronal apoptosis in serum- and potassium-deprived cerebellar granule neurons by inactivating GSK-3β. | |
